Raja, Srikumar M <br/><br/>
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.  [electronic resource] 

 -  Cancer biology & therapy  Jan 2011 
 - 263-76 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1555-8576 
<br/><br/><label>Standard No.: </label>10.4161/cbt.11.2.13959  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Breast Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Dose-Response Relationship, Drug<br/>Drug Evaluation, Preclinical<br/>Drug Synergism<br/>Female<br/>HSP90 Heat-Shock Proteins--antagonists & inhibitors<br/>Humans<br/>Inhibitory Concentration 50<br/>Lapatinib<br/>Mice<br/>Mice, SCID<br/>Pentacyclic Triterpenes<br/>Quinazolines--pharmacology<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Signal Transduction<br/>Trastuzumab<br/>Triterpenes--administration & dosage<br/>Tumor Burden--drug effects<br/>Xenograft Model Antitumor Assays--methods